The latest research shows that METTL3 and YTHDC1 promote the synthesis of EGF and DNA repair protein RAD51 recombinase (RAD51) and improve HR and cell survival during doxorubicin treatment, resulting in drug resistance of BC cells by co-regulating m6A-modified related mRNA (144). The gene discussed is METTL3; the disease is breast cancer.